{"id":"azd7442","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AZD7442 consists of two engineered human monoclonal antibodies (tixagevimab and cilgavimab) that target non-overlapping epitopes on the SARS-CoV-2 spike protein receptor-binding domain. These antibodies work synergistically to neutralize the virus and prevent viral entry into host cells. The antibodies are engineered with extended half-lives to provide prolonged protection against COVID-19.","oneSentence":"AZD7442 is a combination of two monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and provide passive immunity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:09.300Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 in adults and adolescents with inadequate immune response to vaccination"},{"name":"Treatment of mild-to-moderate COVID-19 in high-risk patients"}]},"trialDetails":[{"nctId":"NCT05041907","phase":"PHASE2","title":"Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2021-09-30","conditions":"COVID-19","enrollment":3800},{"nctId":"NCT05315323","phase":"","title":"Clinical Use of EVUSHELD as Pre-exposure Prophylaxis in Real-world Setting in Gulf Cooperation Council Countries","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-06-23","conditions":"COVID-19","enrollment":550},{"nctId":"NCT05281601","phase":"PHASE1","title":"AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-21","conditions":"SARS-CoV-2","enrollment":46},{"nctId":"NCT05648110","phase":"PHASE2, PHASE3","title":"Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study: Study Understanding Pre-Exposure pRophylaxis of NOVel Antibodies (SUPERNOVA) Sub-study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-12-16","conditions":"COVID-19, SARS-CoV-2","enrollment":3882},{"nctId":"NCT05780437","phase":"PHASE3","title":"AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-02-10","conditions":"COVID-19","enrollment":1455},{"nctId":"NCT05712096","phase":"","title":"eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-03-09","conditions":"SARS-CoV-2, COVID-19","enrollment":4000},{"nctId":"NCT04625725","phase":"PHASE3","title":"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-11-21","conditions":"COVID-19","enrollment":5197},{"nctId":"NCT05166421","phase":"PHASE1","title":"Study to Evaluate Pharmacokinetic Comparability Between AZD7442 Co-formulation (AZD8895 + AZD1061) vs AZD8895 and AZD1061 Individually in Adult Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-30","conditions":"Corona Virus Disease","enrollment":224},{"nctId":"NCT05184062","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of AZD7442 in Chinese Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-12-03","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":272},{"nctId":"NCT05667116","phase":"","title":"eVusheld Assessment reaL wORld Effectiveness at UPMC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-01-09","conditions":"SARS-CoV-2, COVID-19","enrollment":4232},{"nctId":"NCT05375760","phase":"PHASE2","title":"A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-06-09","conditions":"Coronavirus Disease 2019 (COVID-19)","enrollment":251},{"nctId":"NCT04507256","phase":"PHASE1","title":"AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT05569408","phase":"","title":"eVusheld Assessment reaL wORld Effectiveness in DoD Health System","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-08-10","conditions":"COVID-19; SARS-CoV-2; 2019 Novel Coronavirus Disease","enrollment":4724},{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT05461378","phase":"","title":"PREP (Pre-Exposure Prophylaxis) of COVID-19","status":"COMPLETED","sponsor":"Ghady Haidar","startDate":"2022-07-26","conditions":"Immuno-Deficiency, COVID-19","enrollment":138},{"nctId":"NCT05917951","phase":"","title":"Study on Determine the Utilisation and Clinical Outcomes of Evusheld in COVID-19 PrEP in China","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-12-24","conditions":"COVID-19","enrollment":248},{"nctId":"NCT04625972","phase":"PHASE3","title":"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-02","conditions":"COVID-19","enrollment":1131},{"nctId":"NCT05438498","phase":"PHASE3","title":"Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2","status":"TERMINATED","sponsor":"MediMergent, LLC","startDate":"2022-06-03","conditions":"SARS-CoV-2 Infection","enrollment":550},{"nctId":"NCT04501978","phase":"PHASE3","title":"ACTIV-3: Therapeutics for Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-04","conditions":"Covid19","enrollment":2753},{"nctId":"NCT04723394","phase":"PHASE3","title":"Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-01-28","conditions":"COVID-19","enrollment":910},{"nctId":"NCT04952402","phase":"PHASE4","title":"SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-07-09","conditions":"Covid19, SARS-CoV2 Infection","enrollment":43},{"nctId":"NCT05437289","phase":"PHASE1","title":"A Study to Evaluate the Safety and Tolerability of AZD7442 in Healthy Chinese Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-10-09","conditions":"Coronavirus Disease 2019 (COVID-19), Healthy Volunteer","enrollment":61},{"nctId":"NCT05629923","phase":"","title":"EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"2022-02-01","conditions":"COVID-19 Pandemic, Transplant-Related Disorder","enrollment":306},{"nctId":"NCT04896541","phase":"PHASE1","title":"Phase I Double-blind, Placebo-controlled Study of AZD7442","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-03-16","conditions":"COVID-19","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Combination of 2 mAbs (AZD8895 and AZD1061)","Combination of 2mAbs(AZD8895 and AZD1061)","AZD8895 + AZD1061","A combination of 2 mAbs (AZD8895 and AZD1061)","Evusheld"],"phase":"phase_3","status":"active","brandName":"AZD7442","genericName":"AZD7442","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD7442 is a combination of two monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and provide passive immunity. Used for Prevention of COVID-19 in adults and adolescents with inadequate immune response to vaccination, Treatment of mild-to-moderate COVID-19 in high-risk patients.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":6,"withResults":4},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}